Boston Scientific Corp


Want a discount? Become a member by purchasing Annual Subscription!
SKU: BSX-1 Category:


Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product innovations, clinical evidence, and the dedication of global teams. In Q3, the company achieved remarkable operational and organic growth, with total sales increasing by 11% operationally and 10% organically compared to Q3 ’22. The adjusted EPS for Q3 reached $0.50, a 15% increase over Q3 ’22, exceeding the guidance range of $0.46 to $0.48. The adjusted operating margin of 26.1% slightly surpassed expectations. Looking ahead to ’23, their team anticipates 8% to 10% organic revenue growth in Q4, aligning with full-year organic guidance of approximately 11%, at the high end of the previous forecast. Operational growth was demonstrated by the regional performance, which showed 9% increase in the US, 11% in Europe, the Middle East, and Africa, and a remarkable 19% in Asia Pacific. Specific business units, such as Urology, Endoscopy, and Peripheral Intervention, experienced double-digit organic growth, reflecting the global success of Boston Scientific’s diverse product portfolio. The company further signed a formal deal to acquire Axonics.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!